ArticleBiomacromolecules2026
Exploring the Antibacterial Potential of Bis-MPA Dendrimers Bearing Cu(II) and Zn(II) Complexes.
Article in Biomacromolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The rise of multidrug-resistant bacteria demands antimicrobial agents that act rapidly and durably. In this work, we aim to develop biodegradable and biocompatible antimicrobial systems by combining the versatile bis-MPA dendritic skeleton with the antibacterial properties of Zn(II) and Cu(II) complexes. The resulting metallodendrimers were synthesized using scalable bis-MPA scaffolds and systematically evaluated for antibacterial activity, cytotoxicity, resistance development and bactericidal kinetics. The dendrimers exhibit broad-spectrum antibacterial efficacy at low micromolar concentrations, with minimum inhibitory concentration values as low as 0.4 μM, while maintaining over 70% viability in fibroblasts and keratinocytes and showing no hemolytic activity toward erythrocytes at bactericidal doses. Second-generation Cu(II) and Zn(II) bis-MPA dendrimers eradicated Bacillus subtilis within 24 h and suppressed Pseudomonas aeruginosa within 4 h, without detectable resistance emergence and with superior activity to ciprofloxacin in the latter. Overall, the combination of rapid antimicrobial action, favorable cytotoxicity profiles, strain-dependent resistance behavior, and scaffold versatility highlights bis-MPA metallodendrimers as promising candidates for next-generation antimicrobial therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.